Drug evaluation: E-5564

  • IDrugs. 2004 Jun;7(6):582-90.
Hari Kumar Ondiveeran  1 ,  Alison Fox-Robichaud
Affiliations
  • 1. McMaster University, Department of Medicine, Regional Critical Care Programme and the Intestinal Disease Research Programme, Faculty of Health Sciences, HSC 4N52, 1200 Main St West, Hamilton, ON, L8N 3Z5, Canada.
PMID: 15197664
Abstract

Eisai Co Ltd is developing the injectable endotoxin antagonist E-5564, for the potential prevention of the pathophysiological effects of endotoxin-mediated responses caused by Bacterial infection, including septic shock.